1
van Leeuwaarde, Rachel S, Dreijerink, Koen M, Ausems, Margreet G, Beijers, Hanneke J, Dekkers, Olaf M, de Herder, Wouter W, van der Horst-Schrivers, Anouk N, Drent, Madeleine L, Bisschop, Peter H, Havekes, Bas, Peeters, Petra H M, Pijnappel, Ruud M, Vriens, Menno R, Valk, Gerlof D
Veröffentlicht in: van Leeuwaarde , R S , Dreijerink , K M , Ausems , M G , Beijers , H J , Dekkers , O M , de Herder , W W , van der Horst-Schrivers , A N , Drent , M L , Bisschop , P H , Havekes , B , Peeters , P H M , Pijnappel , R M , Vriens , M R & Valk , G D 2017 , ' MEN1-Dependent Breast Cancer: Indication for Early Screening? Results From the Dutch MEN1 Study Group ' , Journal of Clinical Endocrinology and Metabolism , vol. 102 , no. 6 , pp. 2083-2090 . https://doi.org/10.1210/jc.2016-3690;
2017
Veröffentlicht in: van Leeuwaarde , R S , Dreijerink , K M , Ausems , M G , Beijers , H J , Dekkers , O M , de Herder , W W , van der Horst-Schrivers , A N , Drent , M L , Bisschop , P H , Havekes , B , Peeters , P H M , Pijnappel , R M , Vriens , M R & Valk , G D 2017 , ' MEN1-Dependent Breast Cancer: Indication for Early Screening? Results From the Dutch MEN1 Study Group ' , Journal of Clinical Endocrinology and Metabolism , vol. 102 , no. 6 , pp. 2083-2090 . https://doi.org/10.1210/jc.2016-3690;
2017
2
de Wild, Sabine R., de Munck, Linda, Simons, Janine M., Verloop, Janneke, van Dalen, Thijs, Elkhuizen, Paula H.M., Houben, Ruud M.A., van Leeuwen, A. Elise, Linn, Sabine C., Pijnappel, Ruud M., Poortmans, Philip M.P., Strobbe, Luc J.A., Wesseling, Jelle, Voogd, Adri C., Boersma, Liesbeth J.
Veröffentlicht in: de Wild , S R , de Munck , L , Simons , J M , Verloop , J , van Dalen , T , Elkhuizen , P H M , Houben , R M A , van Leeuwen , A E , Linn , S C , Pijnappel , R M , Poortmans , P M P , Strobbe , L J A , Wesseling , J , Voogd , A C & Boersma , L J 2022 , ' De-escalation of radiotherapy after primary chemotherapy in cT1–2N1 breast cancer (RAPCHEM; BOOG 2010–03) : 5-year follow-up results of a Dutch, prospective, registry study ' , The Lancet Oncology , vol. 23 , no. 9 , pp. 1201-1210 . https://doi.org/10.1016/S1470-2045(22)00482-X;
2022
Veröffentlicht in: de Wild , S R , de Munck , L , Simons , J M , Verloop , J , van Dalen , T , Elkhuizen , P H M , Houben , R M A , van Leeuwen , A E , Linn , S C , Pijnappel , R M , Poortmans , P M P , Strobbe , L J A , Wesseling , J , Voogd , A C & Boersma , L J 2022 , ' De-escalation of radiotherapy after primary chemotherapy in cT1–2N1 breast cancer (RAPCHEM; BOOG 2010–03) : 5-year follow-up results of a Dutch, prospective, registry study ' , The Lancet Oncology , vol. 23 , no. 9 , pp. 1201-1210 . https://doi.org/10.1016/S1470-2045(22)00482-X;
2022